# Primary Immune Thrombocytopenia (ITP) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/primary-immune-thrombocytopenia-itp

> 2 upcoming FDA catalysts in primary Immune Thrombocytopenia (ITP): efgartigimod iv (ARGX) on June 2028 (primary completion); efgartigimod iv (ARGX) on Jun to Sep 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 16, 2025 | [Sovleplenib primary completion](https://sec-api.dev/pdufa/sovleplenib) | HCM | Primary Immune Thrombocytopenia (ITP) | completed | "NCT05029635 (Phase III Study on HMPL-523 for Treatment of ITP): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-16 (ACTUAL); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05029635)) |
| October 29, 2026 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Primary Immune Thrombocytopenia (ITP) | completed | "NCT05653349 (Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05653349)) |
| Oct 2026 to Jan 2027 | [Ianalumab topline data readout](https://sec-api.dev/pdufa/ianalumab) | NVS | Primary Immune Thrombocytopenia (ITP) | scheduled | "NCT05653349 (Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05653349)) |
| June 2028 | [Efgartigimod iv primary completion](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Primary Immune Thrombocytopenia (ITP) | scheduled | "NCT06544499 (A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544499)) |
| Jun to Sep 2028 | [Efgartigimod iv topline data readout](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Primary Immune Thrombocytopenia (ITP) | scheduled | "NCT06544499 (A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544499)) |

## Drugs

- [Sovleplenib](https://sec-api.dev/pdufa/sovleplenib) (HCM)
- [Ianalumab](https://sec-api.dev/pdufa/ianalumab) (NVS)
- [Efgartigimod iv](https://sec-api.dev/pdufa/efgartigimod-iv) (ARGX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/primary-immune-thrombocytopenia-itp.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Primary Immune Thrombocytopenia (ITP) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/primary-immune-thrombocytopenia-itp

```bibtex
@misc{secapidev_indications_primary_immune_thrombocytopenia_itp_20261116,
  title        = {Primary Immune Thrombocytopenia (ITP) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/primary-immune-thrombocytopenia-itp}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_primary_immune_thrombocytopenia_itp_20261116","title":"Primary Immune Thrombocytopenia (ITP) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/primary-immune-thrombocytopenia-itp","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
